Reduction in the amplitude of shortening and Ca2+ transient by phlorizin and quercetin-3-O-glucoside in ventricular myocytes from streptozotocin-induced diabetic rats

Physiological Research

Volumn 65, Issue 2, 2016, Pages 239-250

  Hamouda, N N ^a   Qureshi, M A ^a   Alkaabi, J M ^a   Oz, M ^a   Howarth, F C ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes mellitus; Phlorizin; Quercetin 3 O glucoside; SGLT inhibitors; Streptozotocin induced diabetic rats; Ventricular myocytes

Indexed keywords

CALCIUM; FLAVONOID; PHLORIZIN; QUERCETIN 3'-O-GLUCOSIDE; STREPTOZOCIN;

ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HEART VENTRICLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FLAVONOIDS; HEART VENTRICLES; MYOCYTES, CARDIAC; PHLORHIZIN; RATS; SARCOPLASMIC RETICULUM; STREPTOZOCIN;

EID: 84975517289     PISSN: 08628408     EISSN: 18029973     Source Type: Journal    
DOI: 10.33549/physiolres.933045     Document Type: Article

References (39)

1. BASSANI JW, YUAN W, BERS DM: Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol 268: C1313-C1319, 1995.
2. BRACKEN N, HOWARTH FC, SINGH J: Effects of streptozotocin-induced diabetes on contraction and calcium transport in rat ventricular cardiomyocytes. Ann NY Acad Sci 1084: 208-222, 2006.
3. CAI Q, LI B, YU F, LU W, ZHANG Z, YIN M, GAO H: Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics. J Diabetes Res 2013: 263845, 2013.
4. CERMAK R, LANDGRAF S, WOLFFRAM S: Quercetin glucosides inhibit glucose uptake into brush-bordermembrane vesicles of porcine jejunum. Brit J Nutr 91: 849-855, 2004.
5. CHAO EC, HENRY RR: SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559, 2010.
6. EHRENKRANZ JRL, LEWIS NG, RONALD KAHN C, ROTH J: Phlorizin: a review. Diabetes Metab Res Rev 21: 31-38, 2005.
7. GEE JM, DUPONT MS, RHODES MJC, JOHNSON IT: Quercetin glucosides interact with the intestinal glucose transport pathway. Free Radic Biol Med 25: 19-25, 1998.
8. GUPTA P, KANWAL A, PUTCHA UK, BULANI Y, SOJITRA B, KHATUA TN, KUNCHA M, BANERJEE SK:Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implication. J Transl Med 11: 80, 2013.
9. 2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem 400: 57-68, 2015.
10. HIROSE M, SHIBAZAKI T, NAKADA T, KASHIHARA T, YANO S, OKAMOTO Y, ISAJI M, MATSUSHITA N, TAIRA E, YAMADA M: Phlorizin prevents electrically-induced ventricular tachyarrhythmia during ischemia in Langendorff-perfused guinea-pig hearts. Biol Pharm Bull 37: 1168-1176, 2014.
11. 2+ sensitivity in ventricular myocytes from streptozotocin-induced diabetic rat. Int J Diabetes Metab 9: 67-74, 2001.
12. 2+ in ventricular myocytes from the Goto-Kakizaki diabetic rat. Mol Cell Biochem 315: 69-74, 2008.
13. 2+ current in rat ventricular myocytes. J Physiol 516: 409-419, 1999.
14. 2+ in streptozotocin-induced diabetic rats. Pflügers Arch - Eur J Physiol 444: 446-451, 2002.
15. HOWARTH FC, AL-SHARHAN R, AL-HAMMADI A, QURESHI MA: Effects of streptozotocin-induced diabetes on action potentials in the sinoatrial node compared with other regions of the rat heart. Mol Cell Biochem 300: 39-46, 2007.
16. HOWARTH FC, QURESHI MA, SOBHY ZHH, PAREKH K, YAMMAHI SR, ADRIAN TE, ADEGHATE E:Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto-Kakizaki rats fed a high-fat diet. Exp Physiol 96:765-777, 2011.
17. IMAMURA M, NAKANISHI K, SUZUKI T, IKEGAI K, SHIRAKI R, OGIYAMA T, MURAKAMI T, KUROSAKI E, NODA A, KOBAYASHI Y, YOKOTA M, KOIDE T, KOSAKAI K, OHKURA Y, TAKEUCHI M, TOMIYAMA H, OHTA M: Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 20: 3263-3279, 2012.
18. INTERNATIONAL DIABETES FEDERATION: International Diabetes Federation ATLAS, 6th edn. International Diabetes Federation, Brussels, 2013.
19. ISMAIL-BEIGI F: Glycemic management of type 2 diabetes mellitus. N Engl J Med 366: 1319-1327, 2012.
20. KATSUNO K, FUJIMORI Y, TAKEMURA Y, HIRATOCHI M, ITOH F, KOMATSU Y, FUJIKURA H, ISAJI M:Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320: 323-330, 2007.
21. KISSEI PHARMACEUTICALS: Discontinuation of the Development of "Remogliflozin" by GlaxoSmithKline. 2009.
22. KOMOROSKI B, VACHHARAJANI N, BOULTON D, KORNHAUSER D, GERALDES M, LI L, PFISTER M:Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85: 520-526, 2009.
23. 2+ transients and contractile responses of diabetic rat cardiomyocytes. Cardiovasc Res 46: 450-462, 2000.
24. LEVI AJ, HANCOX JC, HOWARTH FC, CROKER J, VINNICOMBE J: A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C. Pflügers Arch 432: 930-937, 1996.
25. LI YQ, ZHOU FC, GAO F, BIAN JS, SHAN F: Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem 57: 11463-11468, 2009.
26. MENG W, ELLSWORTH BA, NIRSCHL AA, MCCANN PJ, PATEL M, GIROTRA RN, WU G, SHER PM, ET AL.:Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51: 1145-1149, 2008.
27. 2+ handling, the action potential, and ion currents in rat ventricular myocytes. J Pharmacol Exp Ther 321: 921-929, 2007.
28. RAZAVI S, ZAHRI S, ZARRINI G, NAZEMIYEH H, MOHAMMADI S: Biological activity of quercetin-3-Oglucoside, a known plant flavonoid. Russ J Bioorg Chem 35: 376-378, 2009.
29. SCHAAN BD, DALL'AGO P, MAEDA CY, FERLIN E, FERNANDES TG, SCHMID H, IRIGOYEN MC:Relationship between cardiovascular dysfunction and hyperglycemia in streptozotocin-induced diabetes in rats. Braz J Med Biol Res 37: 1895-1902, 2004.
30. SHA S, DEVINENI D, GHOSH A, POLIDORI D, CHIEN S, WEXLER D, SHALAYDA K, DEMAREST K, ROTHENBERG P: Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13: 669-672, 2011.
31. SHIBAZAKI T, TOMAE M, ISHIKAWA-TAKEMURA Y, FUSHIMI N, ITOH F, YAMADA M, ISAJI M: KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342: 288-296, 2012.
32. SINGH J, CHONKAR A, BRACKEN N, ADEGHATE E, LATT Z, HUSSAIN M: Effect of streptozotocin-induced type 1 diabetes mellitus on contraction, calcium transient, and cation contents in the isolated rat heart. Ann NY Acad Sci 1084: 178-190, 2006.
33. SPURGEON HA, DUBELL WH, STERN MD, SOLLOTT SJ, ZIMAN BD, SILVERMAN HS, CAPOGROSSI MC, TALO A, LAKATTA EG: Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol 447: 83-102, 1992.
34. 2+ homeostasis of isolated adult rat ventricular myocytes. Endocrinology 151: 4446-4454, 2010.
35. TAHRANI AA, BARNETT AH, BAILEY CJ: SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1: 140-151, 2013.
36. TSUJIHARA K, HONGU M, SAITO K, INAMASU M, ARAKAWA K, OKU A, MATSUMOTO M: Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 44: 1174-1180, 1996.
37. VALENTOVÁ K, VRBA J, BANCÍŘOVÁ M, ULRICHOVÁ J, KŘEN V: Isoquercitrin: pharmacology, toxicology, and metabolism. Food Chem Toxicol 68: 267-282, 2014.
38. WANG J, SUN GX, YU L, WU FA, GUO XJ: Enhancement of the selective enzymatic biotransformation of rutin to isoquercitrin using an ionic liquid as a co-solvent. Bioresour Technol 128: 156-163, 2013.
39. ZAMBROWICZ B, FREIMAN J, BROWN PM, FRAZIER KS, TURNAGE A, BRONNER J, RUFF D, SHADOAN M, BANKS P, MSEEH F, RAWLINS DB, GOODWIN NC, MABON R, HARRISON BA, WILSON A, SANDS A, POWELL DR: LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92: 158-169, 2012.